Sai Life Sciences Q2 FY27 Profit Jumps 17% To ₹98 Crore, Revenue Surges 23% As Company Invests ₹621 Crore In Expansion
Mumbai: Sai Life Sciences reported a 17 per cent year-on-year increase in net profit to ₹98 crore for the second quarter ended September 2026, supported by healthy revenue growth and expanding pharmaceutical research and manufacturing operations. Revenue from operations climbed 23 per cent to ₹659 crore, compared with ₹537 crore in the corresponding quarter of FY26, according to the company's…
Sai Life Sciences announced a 17% increase in net profit to ₹98 crore for Q2 FY27, driven by strong revenue growth and investment in expansion. Revenue from operations surged 23%, reaching ₹659 crore, up from ₹537 crore in the same period last year. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) grew by 20% to ₹187 crore, while the profit after tax margin narrowed to 15% from 16%.
Half-year results showed revenue increasing by 17% to ₹1,213 crore and profit after tax rising 19% to ₹172 crore. The company invested ₹621 crore during the first half of FY27 to expand manufacturing capacity and enhance operational capabilities. CFO Siva Chittor emphasized that the investment aims to strengthen the company's future operations.
Managing Director and CEO Krishna Kanumuri noted that customer relationships are shifting towards broader partnerships in drug discovery, development, and manufacturing. Investors will pay close attention to operating margins, capacity expansion, and customer engagement trends as Sai Life Sciences continues its growth plans. This report is based on company filings and is intended for informational purposes only. Investors should conduct their own risk assessment before making investment decisions.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
